1. Academic Validation
  2. Cyclin N-Terminal Domain-Containing-1 Coordinates Meiotic Crossover Formation with Cell-Cycle Progression in a Cyclin-Independent Manner

Cyclin N-Terminal Domain-Containing-1 Coordinates Meiotic Crossover Formation with Cell-Cycle Progression in a Cyclin-Independent Manner

  • Cell Rep. 2020 Jul 7;32(1):107858. doi: 10.1016/j.celrep.2020.107858.
Stephen Gray 1 Emerson R Santiago 2 Joshua S Chappie 2 Paula E Cohen 3
Affiliations

Affiliations

  • 1 Department of Biomedical Sciences and Center for Reproductive Genomics, Cornell University, Ithaca, NY 14853, USA. Electronic address: stephen.gray@nottingham.ac.uk.
  • 2 Department of Molecular Medicine, Cornell University, Ithaca, NY 14853, USA.
  • 3 Department of Biomedical Sciences and Center for Reproductive Genomics, Cornell University, Ithaca, NY 14853, USA. Electronic address: paula.cohen@cornell.edu.
Abstract

During mammalian meiotic prophase I, programmed DNA double-strand breaks are repaired by non-crossover or crossover events, the latter predominantly occurring via the class I crossover pathway and requiring the cyclin N-terminal domain-containing 1(CNTD1) protein. Using an epitope-tagged Cntd1 allele, we detect a short isoform of CNTD1 in vivo that lacks a predicted N-terminal cyclin domain and does not bind cyclin-dependent kinases. Instead, we find that the short-form CNTD1 variant associates with components of the replication factor C (RFC) machinery to facilitate crossover formation, and with the E2 ubiquitin conjugating Enzyme, CDC34, to regulate ubiquitylation and subsequent degradation of the Wee1 kinase, thereby modulating cell-cycle progression. We propose that these interactions facilitate a role for CNTD1 as a stop-go regulator during prophase I, ensuring accurate and complete crossover formation before allowing metaphase progression and the first meiotic division.

Keywords

CDC34; CDK1; CDK2; CNTD1; MutLγ; RFC; WEE1; meiosis; recombination; ubiquitylation.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-10993
    99.97%, Wee1抑制剂